Tetrahydroisoquinolines are an important class of alkaloids displaying high bioactivities.[1] They are present in numerous natural products, and in pharmaceutical drugs and drug candidates, for example, (+)-cryptostyline II, [2a] (+)-cryptostyline III, [2a] and solifenacin (Scheme 1).[2b] Among the various synthetic methods developed in recent decades to afford enantiomerically pure tetrahydroisoquinolines, [1,3] catalytic asymmetric hydrogenation of the corresponding imines shows most promise as a highly efficient and straightforward approach. [4] During the past two decades, a number of catalytic systems for asymmetric hydrogenation [5] and asymmetric transfer hydrogenation [6] of this class of imines have been invented. Using the chiral titanocene developed by Buchwald and Willoughby, 1-methyl-3,4-dihydro-6,7-dimethoxyisoquinoline was hydrogenated with 98 % ee.[5a] Noyori and coworkers initiated research into the Ru II /TsDPEN complex for the highly enantioselective transfer hydrogenation of 3,4-dihydroisoquinolines.[6a] This system was successfully applied in the reduction of 1-(2'-NHR/NO 2 C 6 H 4 )-3,4-dihydroisoquinoline.[6b] Since then, intense research has been focused on this system and modifications have taken place on all components of this catalytic complex, such as, the diamine ligand, the transition metal center, the coordinating h-arene, and the counterion.[5h, 6c-j] Although these titanocene, Ru/ DPEN and Rh/DPEN systems addressed the reduction of 1-alkyl-3,4-dihydroisoquinolines effectively, the asymmetric hydrogenation to enantiomerically pure 1-aryl-tetrahydroisoquinolines remains a challenge, probably owing to the relatively rigid and space-demanding spatial features of these imines. For example, there is no report on the asymmetric hydrogenation of 1-phenyl-3,4-dihydroisoquinoline, a reaction which would lead to the pharmaceutical drug solifenacin (Scheme 1), and the industrial production of this particular tetrahydroisoquinoline depends on an optical resolution of the racemic mixture using tartaric acid. [7] Herein, we report the highly efficient asymmetric hydrogenation of 1-substituted 3,4-dihydroisoquinolines catalyzed by an iridium/f-binaphane complex with excellent reactivity and enantioselectivities (up to 99 % ee and TONs of up to 10 000). The combination of iridium and f-binaphane (Scheme 2) was chosen based on their outstanding performance in asymmetric hydrogenation of a variety of imines from our research.[8] Iridium/diphosphine complexes show more potential for imine reduction in the presence of various additives and possess better activities than other transition metals.[9] At the same time, f-binaphane, which is a strong electron donor and features a flexible ferrocene-based backbone, thus allowing the accommodation of a wide range of substrates around the transition metal center, has been Scheme 1. Structures of (+)-cryptostyline II, (+)-cryptostyline III, and solifenacin.Scheme 2. Structures of chiral phosphine ligands.